Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- Uo
- Uo
- Uo
Lists including Peter
Work Experience
2020
Head of the Global Business & Business Develpment Unit, Senior Vice President
2023
In charge of Global Business and Business Development operations (including Licensing In, Out, Market Access, local collaborations, global and regional CDMO opportunities, import, export, global regulatory, clinical trials, overseas office management, Business Development, Strategies, Partnering, and Alliance Management).
Head of the US Operation
2020
Head of the US Operation at Boryung Corp., a healthcare and pharmaceutical investment and management company. The US Office is responsible for legacy asset acquisitions from global pharma companies. It explores opportunities for Boryung to enter the US market. In addition, it develops business opportunities such as licensing, co-promotions, and co-marketing for the Korean market. Before we changed our corporate name, Boryung, Inc. was fka, Hayan Health Networks, Inc. from January 2020 to April 2022. Boryung, Inc. is the US Office of Boryung Corp in Korea.
2017 - 2019
Chief Executive Officer
2017 - 2019
A member of Boryung Pharm. Company. Global trading, distributing the Rx, OTC, food supplements, cosmetics, and consumer products. Consultation service for pharmaceutical companies conducting in and out-licensing of assets, technologies, and products. Sourcing NCE, IMD, and Gx candidates for clients.
2014 - 2017
Executive Managing Director & Head of Global Business Division
2014 - 2017
In charge of entire Global Business operations (including Licensing In, Out, Market Access, Importing, Exporting, Overseas office management, New Global Business Development, Strategies, Partnering, and Alliance Management). In particular, achievements in Licensing Out of Kanarb, NCE of anti-hypertension developed internally at Boryung.
2010 - 2014
Executive Vice President & COO
2010 - 2014
A member of Hyundai Pharm Company. I am in charge of the entire company's operations, including overseeing research projects and managing 15 researchers, as well as finance, human resources, planning, and operation strategies. The company specializes in the development of incrementally modified drugs (IMDs), mainly CNS assets, which bypass formulation patents to reach the market faster than ordinary generics.
2010 - 2014
Executive Director & Head of Global Business Development and Alliance Management
2010 - 2014
In charge of all global business operations and alliance management. Successfully executed several out & in licensing deals, including China, Europe, SE Asia, and Japan.
2007 - 2010
Director of Global Business Development
2007 - 2010
In Charge of entire Global Business Development, reporting directly to the Chairman of the Board. Successfully executed several out-licensing of products developed internally (including LAPSCOVERY and ORASCOVERY), co-development, technology transfer, and other collaborative deals with multi-national pharmaceutical companies as well as regional leading companies.
2003 - 2007
Senior Manager of Business Development
2003 - 2007
In charge of Licensing-In Oversea products to Korea, new business development, and strategic planning as well as Alliance Management of North American, European, and other English Speaking countries.